Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Balversais a new target anti-cancer star, specializing in FGFR-positive cancers,···【more】
Release date：2024-08-26Recommended：267
Balversa, an innovative anti-cancer targeted drug, accurately snipes FGFR-positi···【more】
Release date：2024-08-26Recommended：280
Balversa is an innovative targeted therapy that effectively inhibits the growth ···【more】
Release date：2024-08-26Recommended：249
Balversa, a new targeted anti-cancer drug, provides new treatment hope for patie···【more】
Release date：2024-08-26Recommended：208
Balversa is a novel targeted anti-cancer drug that inhibits the FGFR signaling p···【more】
Release date：2024-08-26Recommended：164
Balversais an oral, targeted anti-cancer drug that specifically inhibits the FGF···【more】
Release date：2024-08-26Recommended：225
Balversais an oral anticancer drug targeting FGFR mutations for the treatment of···【more】
Release date：2024-08-26Recommended：279
Balversais a new oral anti-cancer drug targeting FGFR, which is specially design···【more】
Release date：2024-08-26Recommended：258
Balversais an oral tyrosine kinase inhibitor for the treatment of non-small cell···【more】
Release date：2024-08-26Recommended：227
Alpelisib has demonstrated a unique efficacy against PIK3CA mutations in HR/HER2···【more】
Release date：2024-08-23Recommended：242
Patients with HR/HER2- advanced breast cancer harboring PIK3CA mutations were si···【more】
Release date：2024-08-23Recommended：332
By specifically inhibiting PIK3CA mutations, Apelis provides a novel therapeutic···【more】
Release date：2024-08-23Recommended：281
